Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933
Debt
Debt-to-Equity RatioN/A
Current Ratio13.91
Quick Ratio13.91
Price-To-Earnings
Trailing P/E Ratio-8.13
Forward P/E Ratio-4.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.68 million
Price / Sales374.05
Cash FlowN/A
Price / CashN/A
Book Value$7.31 per share
Price / Book2.78
Profitability
EPS (Most Recent Fiscal Year)($2.50)
Net Income$-68,520,000.00
Net MarginsN/A
Return on Equity-41.99%
Return on Assets-39.01%
Miscellaneous
Employees96
Outstanding Shares30,910,000
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics (NASDAQ:ACRS) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.98) EPS for the quarter, beating the Zacks' consensus estimate of ($1.00) by $0.02. The biotechnology company earned $1.12 million during the quarter, compared to analysts' expectations of $1 million. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
5 brokers have issued 1 year price targets for Aclaris Therapeutics' stock. Their forecasts range from $36.00 to $53.00. On average, they expect Aclaris Therapeutics' stock price to reach $46.00 in the next twelve months. View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "We rate ACRS as 12-month price target of $50. We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. This could come from positive news flow for each of Aclaris’ three key programs over the next 12-18 months. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $50." (6/12/2018)
- 2. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (6/6/2018)
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS), PTC Therapeutics (PTCT), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Global Blood Therapeutics (GBT), TESARO (TSRO), Heron Therapeutics (HRTX), Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), Endo International (ENDP), Insmed (INSM), Akcea Therapeutics (AKCA) and ACADIA Pharmaceuticals (ACAD).
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal Walker D.O., Co-Founder, Chief Exec. Officer, Pres and Director (Age 48)
- Mr. Christopher V. Powala, Co-Founder and Chief Operating Officer (Age 59)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer and Sec. (Age 59)
- Dr. Stuart D. Shanler M.D., Co-Founder and Chief Scientific Officer (Age 57)
- Mr. Frank Ruffo, Co-Founder and Chief Financial Officer (Age 52)
Has Aclaris Therapeutics been receiving favorable news coverage?
News stories about ACRS stock have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news impact score of 0.09 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Aclaris Therapeutics' major shareholders?
Aclaris Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FRANKLIN RESOURCES INC (10.20%), Franklin Resources Inc. (8.33%), BlackRock Inc. (6.82%), Sofinnova Ventures Inc (4.98%), Citadel Advisors LLC (2.90%) and Point72 Asset Management L.P. (2.36%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Kamil Ali-Jackson, Neal Walker, Ra Capital Management, Llc, Stephen A Tullman and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics.
Which institutional investors are selling Aclaris Therapeutics stock?
ACRS stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, BlackRock Inc., Point72 Asset Management L.P., Franklin Resources Inc., Loomis Sayles & Co. L P, C WorldWide Group Holding A S, Blair William & Co. IL and Rothschild Asset Management Inc.. View Insider Buying and Selling for Aclaris Therapeutics.
Which institutional investors are buying Aclaris Therapeutics stock?
ACRS stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Citadel Advisors LLC, JPMorgan Chase & Co., Foresite Capital Management IV LLC, Summit Trail Advisors LLC, Rock Springs Capital Management LP, Highbridge Capital Management LLC and Foresite Capital Management III LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $20.32.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $613.48 million and generates $1.68 million in revenue each year. The biotechnology company earns $-68,520,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Aclaris Therapeutics employs 96 workers across the globe.
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
